FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009964170> ?p ?o ?g. }

• W2009964170 endingPage "567" @default.
• W2009964170 startingPage "565" @default.
• W2009964170 abstract "A recent analysis by the Blood Pressure Lowering Treatment Trialists' Collaboration revealed that any commonly-used blood pressure (BP)-lowering regimen reduced the risk of total major cardiovascular events, and larger reductions in BP produced larger reductions in the risk. These observations suggest that most of the differences among treatment regimens in their effects on cardiovascular outcomes could be explained by the differences in achieved BP level. However, it may also be true that some treatment regimen is superior or inferior to others with regard to the risk reduction of cardiovascular events. Indeed, the data from dihydropyridine-based calcium antagonist (DHP) trails are consistent in that they could not protect against new-onset heart failure or progression of renal disease in patients with left-ventricular systolic dysfunction or overt proteinuria, respectively. However, a multicenter, randomized, placebo-controlled, double-blind ACTION trial, which compared the effect of long-acting nifedipine or placebo on mortality and cardiovascular morbidity in patients with stable angina, revealed that nifedipine reduced the risk for new-onset overt heart failure by 29%. Further, an open-label, randomized prospective J-MIND trial, which compared the effect of long-acting nifedipine or enalapril, an angiotensin-converting enzyme inhibitor on onset and progression of nephropathy in hypertensive patients with type 2 diabetes, showed that long-acting nifedipine had an equipotent reoprotective effect on diabetic nephropathy. In this paper, we would like to propose our hypothesis that nifedipine may be unique and superior in its effects on heart failure and proteinuria compared with various DHPs. For ensuring our hypothesis, the following clinical issues would be addressed. Does nifedipine treatment alone decrease the progression of renal disease with overt proteinuria? If these answers are yes, are these beneficial effects of nifedipine superior to that of other DHPs with equihypotensive properties? Does nifedipine treatment also reduce oxidative stress markers? Are these unique effects of nifedipine correlated with its anti-oxidative properties? These prospective studies will provide further valuable information whether nifedipine may be a preferred DHP to achieve BP goals in hypertensive patients with systolic dysfunction or overt proteinuria." @default.
• W2009964170 created "2016-06-24" @default.
• W2009964170 creator A5016947629 @default.
• W2009964170 creator A5030113532 @default.
• W2009964170 date "2007-01-01" @default.
• W2009964170 modified "2023-09-24" @default.
• W2009964170 title "Revival of nifedipine, a dihydropyridine-based calcium blocker" @default.
• W2009964170 cites W1497461844 @default.
• W2009964170 cites W1985716618 @default.
• W2009964170 cites W1990845916 @default.
• W2009964170 cites W2016098227 @default.
• W2009964170 cites W2016224008 @default.
• W2009964170 cites W2016400390 @default.
• W2009964170 cites W2047670153 @default.
• W2009964170 cites W2064532629 @default.
• W2009964170 cites W2067569556 @default.
• W2009964170 cites W2093784683 @default.
• W2009964170 cites W2104807853 @default.
• W2009964170 cites W2121708260 @default.
• W2009964170 cites W2138561622 @default.
• W2009964170 cites W2154937731 @default.
• W2009964170 cites W2170077161 @default.
• W2009964170 cites W2297164013 @default.
• W2009964170 doi "https://doi.org/10.1016/j.mehy.2006.05.070" @default.
• W2009964170 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17011717" @default.
• W2009964170 hasPublicationYear "2007" @default.
• W2009964170 type Work @default.
• W2009964170 sameAs 2009964170 @default.
• W2009964170 citedByCount "5" @default.
• W2009964170 countsByYear W20099641702022 @default.
• W2009964170 crossrefType "journal-article" @default.
• W2009964170 hasAuthorship W2009964170A5016947629 @default.
• W2009964170 hasAuthorship W2009964170A5030113532 @default.
• W2009964170 hasConcept C126322002 @default.
• W2009964170 hasConcept C134018914 @default.
• W2009964170 hasConcept C142724271 @default.
• W2009964170 hasConcept C164705383 @default.
• W2009964170 hasConcept C204787440 @default.
• W2009964170 hasConcept C27016395 @default.
• W2009964170 hasConcept C27081682 @default.
• W2009964170 hasConcept C2775940317 @default.
• W2009964170 hasConcept C2778198053 @default.
• W2009964170 hasConcept C2779066535 @default.
• W2009964170 hasConcept C2779561371 @default.
• W2009964170 hasConcept C2779611605 @default.
• W2009964170 hasConcept C2780091579 @default.
• W2009964170 hasConcept C2781184683 @default.
• W2009964170 hasConcept C2781212610 @default.
• W2009964170 hasConcept C2781413609 @default.
• W2009964170 hasConcept C519063684 @default.
• W2009964170 hasConcept C555293320 @default.
• W2009964170 hasConcept C71924100 @default.
• W2009964170 hasConcept C84393581 @default.
• W2009964170 hasConceptScore W2009964170C126322002 @default.
• W2009964170 hasConceptScore W2009964170C134018914 @default.
• W2009964170 hasConceptScore W2009964170C142724271 @default.
• W2009964170 hasConceptScore W2009964170C164705383 @default.
• W2009964170 hasConceptScore W2009964170C204787440 @default.
• W2009964170 hasConceptScore W2009964170C27016395 @default.
• W2009964170 hasConceptScore W2009964170C27081682 @default.
• W2009964170 hasConceptScore W2009964170C2775940317 @default.
• W2009964170 hasConceptScore W2009964170C2778198053 @default.
• W2009964170 hasConceptScore W2009964170C2779066535 @default.
• W2009964170 hasConceptScore W2009964170C2779561371 @default.
• W2009964170 hasConceptScore W2009964170C2779611605 @default.
• W2009964170 hasConceptScore W2009964170C2780091579 @default.
• W2009964170 hasConceptScore W2009964170C2781184683 @default.
• W2009964170 hasConceptScore W2009964170C2781212610 @default.
• W2009964170 hasConceptScore W2009964170C2781413609 @default.
• W2009964170 hasConceptScore W2009964170C519063684 @default.
• W2009964170 hasConceptScore W2009964170C555293320 @default.
• W2009964170 hasConceptScore W2009964170C71924100 @default.
• W2009964170 hasConceptScore W2009964170C84393581 @default.
• W2009964170 hasFunder F4320320912 @default.
• W2009964170 hasIssue "3" @default.
• W2009964170 hasLocation W20099641701 @default.
• W2009964170 hasLocation W20099641702 @default.
• W2009964170 hasOpenAccess W2009964170 @default.
• W2009964170 hasPrimaryLocation W20099641701 @default.
• W2009964170 hasRelatedWork W1990845916 @default.
• W2009964170 hasRelatedWork W2005124541 @default.
• W2009964170 hasRelatedWork W2009964170 @default.
• W2009964170 hasRelatedWork W2052242574 @default.
• W2009964170 hasRelatedWork W2116730178 @default.
• W2009964170 hasRelatedWork W2132305552 @default.
• W2009964170 hasRelatedWork W2326278027 @default.
• W2009964170 hasRelatedWork W2416392402 @default.
• W2009964170 hasRelatedWork W2419581638 @default.
• W2009964170 hasRelatedWork W171956031 @default.
• W2009964170 hasVolume "68" @default.
• W2009964170 isParatext "false" @default.
• W2009964170 isRetracted "false" @default.
• W2009964170 magId "2009964170" @default.
• W2009964170 workType "article" @default.